Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 5/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10989262 | 0.81 | PTGDR2 (0.41) | CSNK2A1PTGDR2ACLYKDM4ECYP2A6 | |
| SCHEMBL9622239 | 0.79 | PLAU (0.61) | PLAUTAAR1TTRKDM4E | |
| SCHEMBL2065922 | 0.79 | KDM4E (0.51) | KDM4ELTA4H | |
| Hydrochloric Acid SCHEMBL10442699 | 0.77 | PLAU (0.59) | PLAUTAAR1TTRKDM4E | |
| SCHEMBL16192822 | 0.77 | PTGDR2 (0.62) | PTGDR2ACLYKDM4E | |
| SCHEMBL10988498 | 0.76 | TP53 (0.50) | TP53MAPK1RAB9APLAUTAAR1 | |
| SCHEMBL2067282 | 0.74 | KDM4E (0.40) | CSNK2A1PTGDR2ACLYKDM4ECYP2A6 | |
| SCHEMBL10991055 | 0.73 | TP53 (0.58) | TP53MAPK1RAB9APLAUTAAR1 | |
| SCHEMBL11037554 | 0.72 | CYP2A6 (0.44) | TP53RAB9ACSNK2A1PTGDR2ACLY | |
| SCHEMBL9601457 | 0.71 | CSNK2A1 (0.51) | CSNK2A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507551-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-13 | — | — | US | claimed |
| US-20090042976-A1 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIS (US) | 2009-02-12 | — | — | US | claimed |
| US-8778913-B2 | Antimicrobial compositions for treating microbial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) | 2014-06-05 | — | — | US | disclosed |
| US-8507551-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-13 | — | — | US | disclosed |
| US-8148352-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090042976-A1 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIS (US) | 2009-02-12 | — | — | US | disclosed |
| EP-2020857-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | The Regents of the University of California (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007133712-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-22 | — | — | WO | disclosed |
| US-4548994-A | IMMOBILIZATION ON AFFINITY RESIN | THE UPJOHN COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0057600-B1 | AFFINITY RESINS AND THEIR USE IN ISOLATING BACTERIAL LUCIFERASE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1985-05-08 | — | — | EP | disclosed |
| US-4412001-A | IMMOBILIZATION BY BINDING TO A LIGAND-SPACER-SUPPORT; WASHING; DESORPTION; PURIFICATION | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1983-10-25 | — | — | US | disclosed |
| EP-0057600-A2 | Affinity resins and their use in isolating bacterial luciferase | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1982-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | SERPINB1, CUTA, SRRT | TP53 1574/4885MAPK1 2270/4885RAB9A 1745/4885 |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | MPO, CUTA, STING1 | TP53 1266/4885MAPK1 2710/4885RAB9A 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.